Alejandro Andreu, MD
Internal Medicine · Aventura, FLNPI 1215095872
Payments from drug & device makers
Across 430 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$999
- AstraZeneca$996
- Johnson & Johnson$643
- GSK$619
- Lilly USA, LLC$618
- Pfizer$559
- plus $4K from 36 others
What the payments were for
- Speaking & faculty fees$190%
- Food & beverage$8,51898%
- Education$1301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 65 | $999 |
| AstraZeneca | 43 | $996 |
| Johnson & Johnson(2 entities) | 35 | $643 |
| GSK | 27 | $619 |
| Lilly USA, LLC | 36 | $618 |
| Pfizer | 29 | $559 |
| Boehringer Ingelheim | 22 | $514 |
| Sumitomo Pharma America, Inc. | 21 | $448 |
| Novo Nordisk | 14 | $359 |
| Radius Health, Inc. | 14 | $318 |
| Astellas Pharma US Inc | 10 | $289 |
| Novartis | 13 | $282 |
| Sanofi-aventis U.S. LLC | 14 | $262 |
| AbbVie(2 entities) | 12 | $257 |
| E.r. Squibb & Sons, L.L.C. | 7 | $148 |
| Gilead | 8 | $134 |
| Abbott | 6 | $125 |
| Exact Sciences | 5 | $119 |
| Merck | 6 | $99 |
| Sunovion Pharmaceuticals Inc. | 4 | $94 |
| Ardelyx, Inc. | 4 | $87 |
| Bayer | 4 | $80 |
| Dexcom, Inc. | 3 | $79 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| Amarin Pharma, Inc. | 2 | $41 |
| Currax Pharmaceuticals LLC | 2 | $35 |
| Nevro Corp. | 1 | $32 |
| Phadia US Inc. | 2 | $29 |
| Eisai Inc. | 1 | $26 |
| Heartflow, Inc. | 1 | $25 |
| Redhill Biopharma Inc. | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Biogen | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Organogenesis Inc. | 1 | $15 |
| Acerus Pharmaceuticals Corporation | 1 | $14 |
| Advanced Respiratory, Inc | 1 | $14 |
| Medtronic | 1 | $13 |
How this compares
$8,666 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 161 | $194,218 |
| FarxigaDapagliflozin Propanediol | 117 | $138,476 |
| ProliaDenosumab | 47 | $82,684 |
| MounjaroTirzepatide | 62 | $78,844 |
| JardianceEmpagliflozin | 53 | $74,683 |
| JanuviaSitagliptin Phosphate | 51 | $67,137 |
| XareltoRivaroxaban | 48 | $54,777 |
| TrulicityDulaglutide | 32 | $38,768 |
| EntrestoSacubitril/Valsartan | 36 | $37,251 |
| OzempicSemaglutide | 15 | $17,334 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $17,245 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $16,288 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $15,643 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $15,502 |
| Repatha SureclickEvolocumab | 12 | $13,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $559 | $194,218161 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $996 | $172,420165 claims |
| Lilly USA, LLCMounjaro, Trulicity | $618 | $117,61294 claims |
| AmgenProlia | $999 | $82,68447 claims |
| Boehringer IngelheimJardiance | $514 | $74,68353 claims |
| MerckJanuvia | $99 | $67,13751 claims |
| Johnson & JohnsonXarelto | $643 | $54,77748 claims |
| NovartisEntresto | $282 | $37,25136 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $619 | $31,79041 claims |
| Novo NordiskOzempic | $359 | $17,33415 claims |
| AbbVieLinzess, Synthroid | $257 | $16,64457 claims |
| Astellas Pharma US IncMyrbetriq | $289 | $12,83914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Aventura
- Marc SaltzmanAventura$8.9M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.